These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16470538)

  • 1. PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.
    Lagonigro MS; Tamborini E; Negri T; Staurengo S; Dagrada GP; Miselli F; Gabanti E; Greco A; Casali PG; Carbone A; Pierotti MA; Pilotti S
    J Pathol; 2006 Apr; 208(5):615-23. PubMed ID: 16470538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors.
    Bozzi F; Tamborini E; Negri T; Pastore E; Ferrari A; Luksch R; Casanova M; Pierotti MA; Bellani FF; Pilotti S
    Cancer; 2007 Apr; 109(8):1638-45. PubMed ID: 17342771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
    Tamborini E; Miselli F; Negri T; Lagonigro MS; Staurengo S; Dagrada GP; Stacchiotti S; Pastore E; Gronchi A; Perrone F; Carbone A; Pierotti MA; Casali PG; Pilotti S
    Clin Cancer Res; 2006 Dec; 12(23):6920-8. PubMed ID: 17145809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.
    Tamborini E; Casieri P; Miselli F; Orsenigo M; Negri T; Piacenza C; Stacchiotti S; Gronchi A; Pastorino U; Pierotti MA; Pilotti S
    J Pathol; 2007 Jun; 212(2):227-35. PubMed ID: 17471466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDGFRalpha/beta expression correlates with the metastatic behavior of human colorectal cancer: a possible rationale for a molecular targeting strategy.
    Wehler TC; Frerichs K; Graf C; Drescher D; Schimanski K; Biesterfeld S; Berger MR; Kanzler S; Junginger T; Galle PR; Moehler M; Gockel I; Schimanski CC
    Oncol Rep; 2008 Mar; 19(3):697-704. PubMed ID: 18288404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.
    Liegl B; Gülly C; Reich O; Nogales FF; Beham A; Regauer S
    Histopathology; 2007 Mar; 50(4):448-52. PubMed ID: 17448020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors.
    Welin S; Fjällskog ML; Saras J; Eriksson B; Janson ET
    Neuroendocrinology; 2006; 84(1):42-8. PubMed ID: 17047316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
    Liegl B; Leithner A; Bauernhofer T; Windhager R; Guelly C; Regauer S; Beham A
    Histopathology; 2006 Dec; 49(6):576-81. PubMed ID: 17163842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
    Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
    Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
    Perrone F; Jocollè G; Pennati M; Deraco M; Baratti D; Brich S; Orsenigo M; Tarantino E; De Marco C; Bertan C; Cabras A; Bertulli R; Pierotti MA; Zaffaroni N; Pilotti S
    Eur J Cancer; 2010 Oct; 46(15):2837-48. PubMed ID: 20692828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
    Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
    Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).
    Negri T; Bozzi F; Conca E; Brich S; Gronchi A; Bertulli R; Fumagalli E; Pierotti MA; Tamborini E; Pilotti S
    J Pathol; 2009 Jan; 217(1):103-12. PubMed ID: 18973210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade.
    Rozeman LB; Hameetman L; van Wezel T; Taminiau AH; Cleton-Jansen AM; Hogendoorn PC; Bovée JV
    J Pathol; 2005 Sep; 207(1):61-71. PubMed ID: 16007578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer.
    Gockel I; Moehler M; Frerichs K; Drescher D; Trinh TT; Duenschede F; Borschitz T; Schimanski K; Biesterfeld S; Herzer K; Galle PR; Lang H; Junginger T; Schimanski CC
    Oncol Rep; 2008 Oct; 20(4):845-50. PubMed ID: 18813825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
    Fjällskog ML; Lejonklou MH; Oberg KE; Eriksson BK; Janson ET
    Clin Cancer Res; 2003 Apr; 9(4):1469-73. PubMed ID: 12684421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.